AZN : Imfinzi Plus Novel Immunotherapies Improve Clinical Outcomes For Patients With Lung Cancer

AstraZeneca PLC (AZN,AZN.L) said Friday that results from the large, randomized COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi or durvalumab improved progression-free survival or PFS and objective response rate or ORR compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer or NSCLC who had not progressed after concurrent chemoradiation therapy or CRT.

After a median follow-up of 11.5 months, the results of an interim analysis showed IMFINZI in combination with oleclumab reduced the risk of disease progression or death by 56%, and in combination with monalizumab by 35%, when compared to Imfinzi alone in Stage III NSCLC patients following CRT.

The 10-month PFS rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.

The results also showed an increase in the primary endpoint of confirmed ORR for IMFINZI plus oleclumab over IMFINZI alone and for IMFINZI plus monalizumab over IMFINZI alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
HSBC Holdings Plc shares were gaining In London trading as well as in pre-market activity on the NYSE after the Asia-focused lender backed its positive outlook after reporting significantly higher third-quarter profit. Further, the company announced share buyback of $2 billion, which will be commenced shortly. Walmart is recalling certain Aromatherapy Room Spray due to the possible presence of a rare and dangerous bacteria that is suspected to be behind two deaths in the United States, the U.S. Consumer Product Safety Commission said. The recall involves about 3,900 bottles of Better Homes and Gardens-branded Essential Oil Infused Aromatherapy Room Spray with Gemstones in six different scents. Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port.
Follow RTT